Frequently Asked Questions
The market is segmented based on Global Point of Care Infectious Disease Diagnostics Market, By Product (Consumables, Instruments, and Software and Services), Technology (Lateral Flow, Agglutination Assays, Flow-Through, and Solid Phase), Application (HIV, Tropical Disease, Liver Disease, Inflammatory Disease, Respiratory Disease, Hospital Associated Infections, and Sexual Health Disorders), End User (Hospitals, Healthcare Centers, Laboratories, Independent Diagnostic Centers, and Home Care Settings) – Industry Trends and Forecast to 2031.
.
The Global Point Of Care Infectious Disease Diagnostics Market size was valued at USD 2.20 USD Billion in 2023.
The Global Point Of Care Infectious Disease Diagnostics Market is projected to grow at a CAGR of 14.32% during the forecast period of 2024 to 2031.
The major players operating in the market include Siemens Healthineers AG (Germany), Trivitron Healthcare (India), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.), Quest Diagnostics Incorporated (U.S.), BD (U.S.), Chembio Diagnostics, Inc. (U.S.), Trinity Biotech (Ireland), Cardinal Health (U.S.), Bio-Rad Laboratories Inc. (U.S.), bioMérieux SA (France), Thermo Fisher Scientific Inc. (U.S.), QuidelOrtho Corporation (U.S.), OJ-Bio Limited (U.K.).
The market report covers data from the U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, Rest of South America.